Grant: Idea to Innovation
University of Guelph
$125,000.00
Compartmentalized Linker Array (CLA) for next-generation multiplexed bioassays
FY 2024-25
Summary
Multiplexed protein assays are extensively used in biological and biomedical research, constituting a substantial part of the biotechnology industry. However, current technologies in the market suffer from issues such as high costs, limited customizability, and steep learning curves, restricting the research scope of the customers and slowing down their scientific discovery process.
Recently, Dr. Li's laboratory developed a new technology called Compartmentalized Linker Array (CLA) to address these challenges. The CLA enables low-cost and highly customizable multiplexed protein measurement. Customers can select their analytes of interest and bioreagents, and add or remove analytes without causing cross-contamination and interference. Additionally, the assay procedure can be completed using standard micro-pipettes and fluorescence microscopes. The CLA prototype has demonstrated success in multiplexed protein analysis. As evidenced in our market analysis supported by an NSERC L2M phase 0 grant, there is a strong demand for the CLA technology from both biotech industry and biomedical research institutes.
This project aims to promote the adoption of our CLA technology in the target market. The goals include developing a mass-manufacturable method, validating the assays, evaluating it with potential customers, and establishing commercial-scale manufacturing capacity to meet customer needs. Moreover, the CLA's application will be extended to measure the proteins in extracellular vesicles (EVs) to meet the rapidly growing demands from EV researchers. These critical steps will strengthen the commercial value and licensing opportunities of this technology, making it market-ready for successful commercialization.
Program
Idea to Innovation
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
592662-2024
Name nom
Li, Huiyan H
Department département
Engineering, School of
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Compartmentalized Linker Array (CLA) for next-generation multiplexed bioassays
Keywords
assay validation; customizable; extracellular vesicles; high specificity; low-cost; mass manufacture; multiplexed bioassay; protein quantification; scalable; simple-to-implement
Application summary
Multiplexed protein assays are extensively used in biological and biomedical research, constituting a substantial part of the biotechnology industry. However, current technologies in the market suffer from issues such as high costs, limited customizability, and steep learning curves, restricting the research scope of the customers and slowing down their scientific discovery process.
Recently, Dr. Li's laboratory developed a new technology called Compartmentalized Linker Array (CLA) to address these challenges. The CLA enables low-cost and highly customizable multiplexed protein measurement. Customers can select their analytes of interest and bioreagents, and add or remove analytes without causing cross-contamination and interference. Additionally, the assay procedure can be completed using standard micro-pipettes and fluorescence microscopes. The CLA prototype has demonstrated success in multiplexed protein analysis. As evidenced in our market analysis supported by an NSERC L2M phase 0 grant, there is a strong demand for the CLA technology from both biotech industry and biomedical research institutes.
This project aims to promote the adoption of our CLA technology in the target market. The goals include developing a mass-manufacturable method, validating the assays, evaluating it with potential customers, and establishing commercial-scale manufacturing capacity to meet customer needs. Moreover, the CLA's application will be extended to measure the proteins in extracellular vesicles (EVs) to meet the rapidly growing demands from EV researchers. These critical steps will strengthen the commercial value and licensing opportunities of this technology, making it market-ready for successful commercialization.